Ofev® (nintedanib): Information on severe liver injury and the need for regular monitoring of liver function associated with the use in patients with idiopathic pulmonary fibrosis (IPF)


User Rating: 4 / 5

Star ActiveStar ActiveStar ActiveStar ActiveStar Inactive


Date: 5 January 2018



Cases of drug-induced liver injury (DILI) in patients treated with Ofev® have been reported worldwide in the post-marketing period, including a case of severe liver injury associated with a fatal outcome.

Healthcare professionals are advised to monitor transaminases and bilirubin levels:

Dose reduction or treatment interruption is recommended for managing transaminase elevations according to the current product information.


Please refer to the Direct Healthcare Professional Communication (DHPC) letter issued by Boehringer Ingelheim (Malaysia) Sdn. Bhd. in agreement with NPRA for further information.